

1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Watowich et al.

Group Art Unit: 1632

Serial No.: 09/981,286

Examiner: Unknown

Filed: October 15, 2001

Docket No.: 265.00260101

Confirmation No.: 4993

Title: DRUG DISCOVERY METHODS

RECEIVED

JUN 24 2002

Assistant Commissioner for Patents

Box Sequence, P.O. Box 2327

Arlington, VA 22202

TECH CENTER 1600/2900

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

- ☒ **Small entity status is entitled to be asserted in the above-identified application.**
- ☒ An itemized return postcard.
- ☐ An Information Disclosure Statement (\_\_\_ pgs); copies of \_\_\_ applications; 1449 forms (\_\_\_ pgs); and copies of \_\_\_ documents cited on the 1449 forms.
- ☐ A certified copy of a \_\_\_ application, Serial No. \_\_\_, filed \_\_\_, the right of priority of which is claimed under 35 U.S.C. §119.
- ☒ Other: Communication Regarding Resubmission of Substitute Computer Readable Form (CRF) Copy of Sequence Listing (2 pgs); Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (1 pg), copy of CRF Problem Report (1 pg), and one disk.
- ☐ Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$9 =	
Independent Claims				x \$42 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$140 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

**CERTIFICATE UNDER 37 C.F.R. §1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on this 14 day of June, 2002.

MUETING, RAASCH & GEBHARDT, P.A.

Customer Number: 26813



26813

PATENT TRADEMARK OFFICE

By:


*David L. Provence*

Name: David L. Provence

Reg. No.: 43,022

Direct Dial: 612-305-1005

Facsimile: 612-305-1228



PATENT  
Docket No. 265.00260101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Watowich et al. ) Group Art Unit: 1632  
Serial No.: 09/981,286 ) Examiner: Unknown  
Confirmation No.: 4993 )  
Filed: October 15, 2001 )  
For: DRUG DISCOVERY METHODS

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

**COMMUNICATION REGARDING RESUBMISSION OF  
SUBSTITUTE COMPUTER READABLE FORM (CRF) COPY  
OF SEQUENCE LISTING**

Assistant Commissioner for Patents  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated May 7, 2002. Copies of the Notice and the CRF Problem Report are attached hereto.

In compliance with said Notice, enclosed is a substitute computer readable form (CRF) copy of the "Sequence Listing", as the original CRF was damaged and/or unreadable.

In accordance with 37 C.F.R. §1.821, it is respectfully submitted that the information recorded on the substitute CRF copy is identical to that of the CRF copy and the written sequence listing originally filed with the U.S. Patent and Trademark Office on January 28, 2002. The substitute CRF copy of the sequence listing does not contain new matter.

**Communication Regarding Resubmission of  
Substitute Computer Readable Form (CRF) Copy  
of Sequence Listing**

Page 2

Applicant(s): Watowich et al.

Serial No. 09/981,286

Confirmation No. 4993

Filed: October 15, 2001

Title: DRUG DISCOVERY METHODS

---

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number if prosecution of this application may be assisted thereby.

**CERTIFICATE UNDER 37 C.F.R. 1.8:**

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Box Sequence, P.O. Box 2327, Arlington, VA 22202, on this 14 day of June, 2001.

  
David L. Provence

June 14, 2002  
Date

Respectfully submitted for

Watowich et al.

By

Muetting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220


Facsimile: (612)305-1228

**Customer Number 26813**



**26813**


PATENT TRADEMARK OFFICE

By: 

David L. Provence

Reg. No. 43,022

Direct Dial (612) 305-1005



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/981,286	10/15/2001	Stanley J. Watowich	265.00260101

CONFIRMATION NO. 4993

26813

MUETING, RAASCH & GEBHARDT, P.A.  
P.O. BOX 581415  
MINNEAPOLIS, MN 55458

**RECEIVED**

JUN 24 2002

FORMALITIES LETTER



\*OC00000008044740\*

TECH CENTER 1600/2900

Date Mailed: 05/07/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

OLPE

## CRF Problem Report



The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/98/286  
Filing Date: 10/15/2001  
Date Processed by STIC: 3/4/2002

RECEIVED

JUN 24 2002

STIC Contact: Mark Spencer, 703-308-4212

TECH CENTER 1600/2900

### Nature of Problem:

The CRF (was):

- ☒ (circle one) Damaged or Unreadable (for Unreadable, see attached)  
☐ Blank (no files on CRF) (see attached)  
☐ Empty file (filename present, but no bytes in file) (see attached)  
☐ Virus-infected. Virus name: \_\_\_\_\_ The STIC will not process the CRF.  
☐ Not saved in ASCII text  
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.  
☐ Did not contain a Sequence Listing. (see attached sample)  
☐ Other: \_\_\_\_\_

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.  
SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202